| Particulars (Rupees in Crores.) | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 | Sept-2023 |
|---|---|---|---|---|---|
Gross Sales | 343.8 | 292.51 | 291.69 | 286.76 | 312.98 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 343.8 | 292.51 | 291.69 | 286.76 | 312.98 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.99 | 9.44 | 8.62 | 1.94 | 1.81 |
Total Income | 348.79 | 301.95 | 300.32 | 288.7 | 314.79 |
Total Expenditure | 258.18 | 222.43 | 221.77 | 221.6 | 254.59 |
PBIDT | 90.61 | 79.52 | 78.54 | 67.09 | 60.2 |
Interest | 25.55 | 23.74 | 24.2 | 26.22 | 23.24 |
PBDT | 65.05 | 55.79 | 54.34 | 40.87 | 36.96 |
Depreciation | 28.28 | 27.11 | 26.63 | 26.71 | 27.79 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 24.96 | 15.91 | 11.26 | 12.85 | 12.94 |
Deferred Tax | -6.13 | -1.29 | -8.05 | -3.39 | -5.34 |
Reported Profit After Tax | 17.94 | 14.06 | 24.5 | 4.7 | 1.57 |
Minority Interest After NP | 0.01 | 0 | 0 | 0.12 | -0.04 |
Net Profit after Minority Interest | 17.94 | 14.06 | 24.5 | 4.58 | 1.61 |
Extra-ordinary Items | 0 | 0 | 3.64 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 17.94 | 14.06 | 20.86 | 4.58 | 1.61 |
EPS (Unit Curr.) | 1.83 | 1.46 | 2.82 | 0.53 | 0.19 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 9.78 | 9.78 | 8.68 | 8.68 | 8.68 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 26.35 | 27.18 | 26.92 | 23.39 | 19.23 |
PBDTM(%) | 18.92 | 19.07 | 18.62 | 14.25 | 11.8 |
PATM(%) | 5.21 | 4.8 | 8.39 | 1.63 | 0.5 |
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
Shilpa Medicare is the first Indian company to gain approval for Phase III trials of Recombinant Human Albumin.
The European Directorate for the Quality of Medicines & Healthcare (EDQM) gave Shilpa Pharma Lifesciences, the company's subsidiary, the Certificate of Suitability (CEP) for Nifedipine.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.
According to the firm, the NDA submission package is based on three clinical trials, many pre-clinical investigations.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
